Hormone therapy and risk of venous thromboembolism among postmenopausal women - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue Climacteric Année : 2009

Hormone therapy and risk of venous thromboembolism among postmenopausal women

Résumé

Venous thromboembolism, either deep vein thrombosis or pulmonary embolism, is a serious side-effect of postmenopausal hormone therapy. Current use of oral estrogens increases the risk of venous thromboembolism, especially during the first year of treatment, but past users of hormone therapy have a similar risk as never-users. Among women at high risk for venous thromboembolism (for example, thrombogenic mutations, obesity), oral estrogens use further enhances the thrombotic risk. Recent studies have shown that transdermal estrogens might be safe with respect to thrombotic risk. The difference in thrombotic risk between oral and transdermal estrogens may be partially explained by changes in hemostasis. Few data are currently available regarding the impact of progestogens on venous thromboembolism risk, but norpregnane derivatives might be thrombogenic. Individual assessment of the benefit-risk ratio is needed before initiating treatment and oral estrogens should be avoided among women at high risk for venous thromboembolism.
Fichier principal
Vignette du fichier
Canonico_Climacteric_2009.pdf (258.89 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)
Loading...

Dates et versions

inserm-01142910 , version 1 (16-04-2015)

Identifiants

Citer

Marianne Canonico, Pierre-Yves Scarabin. Hormone therapy and risk of venous thromboembolism among postmenopausal women. Climacteric, 2009, 12 (s1), pp.76-80. ⟨10.1080/13697130903006837⟩. ⟨inserm-01142910⟩
240 Consultations
413 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More